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Abstract 
Inflammatory myofibroblastic tumor is a distinctive lesion composed of  myofibroblastic spindle shaped cells ac-
companied by inflammatory  infiltrate  that may arise in various organs. It is believed to be a noneoplastic  inflam-
matory condition, although this is still controversial. The recognition of inflammatory myofibroblastic tumor as 
an  entity  is important especially to avoid unnecessary surgery. A few cases have been reported in the oral  cavity. 
This report primarily presents a case of inflammatory myofibroblastic  tumor  that arose in the floor of mouth of 
a 23-year-old woman. The  proliferating spindle cells were immunoreactive for vimentin, smooth  muscle  actin, 
and muscle specific actin and negative for desmin, AE1/AE3, S-100,  CD68, MyoD1 and caldesmon. In an attempt 
to assess the potential  neoplastic  nature of this lesion, immunohistochemical expression of ALK protein was 
performed, although no immunoreactivity was detected. Also, the presence  of well differentiated myofibroblasts 
identified by fibronectin is  discussed, as well as the importance in establishing an immunoprofile to  better con-
solidate the diagnosis. We conclude that the study of fibronectin in case series may aid the diagnosis as well as the 
prediction of the  tumor  course.   
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Introduction
Inflammatory myofibroblastic tumor (IMT) is a rare en-
tity included in a heterogeneous group of spindle cell 
proliferations, which encompasses a broad phenotypic 
and biologic spectrum of diseases ranging from reactive 
lesions to benign neoplasms (1). Tumours and tumour-
like lesions of myofibroblasts may present diagnos-
tic difficulty because of their rarity and uncertainties 
in identifying the myofibroblast (2). So, immunohis-
tochemistry and electron microscopy are emphasized 
as being important for maximum diagnostic confidence 
in some myofibroblastic lesions (2). The expression of 
myofibroblast by characteristic proteins as α-smooth-
muscle actin and fibronectin are essential to diagnos-
ing myofibroblastic lesions (3,4). The purpose of this 
study is primarily to present a case of IMT in the floor 
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of the mouth, describing its clinical aspect, immuno-
phenotype and management, showing for the first time 
myofibroblastic fibronectin expression contributing to 
the knowledge and characterization of this entity.
Case report
A 23-year-old white woman presented for evaluation of 
a painless swelling with a three-week history of pro-
gressive growing on the floor of the mouth. Her medi-
cal and surgical histories were unremarkable, and she 
denied any previous lesions or local trauma. Intraoral 
examination revealed a 3 cm pedunculated reddish exo-
phytic mass, with a rubbery consistency, attached to the 
mucosa (Fig. 1). The overlying mucosa presented ulcer-
ated areas with no discharge. 
On the basis of the clinical findings, glandular neoplasm, 
noneoplastic proliferative process or malignant tumor 
were considered as differential diagnosis. An incisional 
biopsy was performed and, microscopic examination 
revealed an ulcerated nodular mass composed of prolif-
erating spindle cells in a predominantly myxoid stroma 
admixed with a variable amount of acute and chronic 
inflammatory cells along with a rich vascular network 
(Fig. 2A). Towards the periphery, the lesion was more 
cellular with a focal fascicular arrangement of the spin-
dle cells. In all fields, an inflammatory component was 
prominent and was formed mainly by neutrophils and 
lymphocytes with a few plasma cells, histiocytes and 
Fig. 1. Clinical view of the mandible showing the round pe-
dunculated reddish mass with a rubbery consistency, atta-
ched to the floor of mouth mucosa.
Fig. 2. Photomicrographs of Inflammatory myofibroblastic tumor. A, spindle tumor cells scattered in a 
loosely and myxoid background with inflammatory proliferation; in detail, myofibroblasts and eosinophils 
(hematoxylin and eosin stain). B, immunohistochemical staining of SMA in spindled myofibroblasts. C, 
diffuse immunostaining of HHF-35 also showed in spindled myofibroblasts. D, strong immunohistochemi-
cal staining of Fibronectin in spindled myofibroblasts. Streptavidin-biotin (B, C and D). Scale bars indicate 
50 µm.
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eosinophils. The spindle cells exhibited plump tapering 
vesicular nuclei and were haphazardly arranged (Fig. 
2A). Non-cohesive larger stellate or polygonal cells with 
ovoid vesicular nuclei and prominent nucleoli were scat-
tered. Nuclear atypia and mitosis were not evident.
Additionally, immunohistochemistry was performed 
with proliferating spindle cells showing intense and dif-
fuse positivity for vimentin (M0725, DakoCytomation, 
Carpinteria, CA, USA), smooth muscle actin (SMA; 
M0851, DakoCytomation) (Fig. 2B) and muscle specific 
actin (HHF-35; M0635, DakoCytomation) (Fig. 2C). The 
immunostaining for desmin, however, was negative as 
were also negative reactions to AE1/AE3 (M3515, Da-
koCytomation), S-100 (Z311, DakoCytomation), CD68 
(M0814, DakoCytomation), MyoD1 (M3512, DakoCy-
tomation), and caldesmon (M3557, DakoCytomation). 
In an attempt to delineate the potential neoplastic nature 
of this lesion, we assessed the immunohistochemical 
expression of ALK protein (M7195, DakoCytomation), 
although none reactivity was found. A diagnosis of IMT 
was established. Furthermore, fibronectin (A0245, Da-
koCytomation) immunostaining was performed, show-
ing strong positivity in spindle cells (Fig. 2D), corrobo-
rating with a myofibroblastic phenotype.
A surgical excision was carried out (Fig. 3) and post-
operative histopathological examination confirmed the 
initial diagnosis of IMT. The postoperative course was 
unremarkable. The patient was satisfied with her quality 
of life and remained disease free at the time of her last 
follow-up, 2 years after surgery.      
Discussion
Oral IMT is a very rare lesion which along with its non-
specific clinical appearance may pose difficulties to 
diagnosis and management. Its rapid growth rate may 
simulate a malignant disorder and therefore warrants a 
comprehensive histopathologic assessment (5). Origi-
nally reported in the lung, extra-pulmonary IMTs have 
been described (1), including head and neck region (6), 
mainly in the aerodigestive tract, major salivary glands 
and soft tissues of the neck (1,7,8). A limited number 
of patients with oral IMT have been reported (5), thus 
contributing with the unspecified pattern of clinical 
aspects and clues to diagnosis. In the oral mucosa, the 
most reported sites of occurrence are submandibular re-
gion (9), parotid duct (7), retromolar area (10), alveolar 
mucosa of the molar region (5), tongue (11), maxilla (7) 
and the hard palate (6). Typically, oral IMTs have been 
described as a well circumscribed, solitary nodule or 
mass, frequently pedunculated, and rubbery consisten-
cy, as the present one, have been reported (5).
The etiology of most oral IMTs remains controversial. 
Some authors widely consider it a benign neoplastic 
lesion (6), and others support a reactive etiology (10), 
since the rapid growth and subsequent indolent behav-
ior of most oral IMT are similar to that of many com-
mon reactive oral lesions (5). Differently, in other sites, 
this condition can behave in a more aggressive or even 
malignant way (11), constituting a true neoplastic pro-
cess due to the potential for local recurrence, develop-
ment of multifocal tumors, infiltrative local growth, and 
even distant metastasis (12). 
Histologically, various aspects can be seen. In the cur-
rent case one of the patterns was observed; loosely ar-
ranged myofibroblasts in an edematous and myxoid 
background with plasma cells, lymphocytes, eosino-
phils, and blood vessels (5,10). A second configura-
tion that can occur is distinguished by the presence of 
dense aggregates of spindle cells arranged in a variable 
myxoid or collagenized background, admixed with a 
distinctive inflammatory infiltrate (13). Finally, a third 
pattern of IMT is characterized by prominent collagen 
sheets, resembling scar tissue, with scattered plasma 
cells and eosinophils (5). Cytological atypia with nu-
clear pleomorphism and increased mitotic activity are 
uncommon features (5,6), and may be associated with 
malignant transformation (5).
Immunoprofile is helpful in the establishment of the diag-
nosis of IMT especially by the identification of myo-
fibroblasts. The myofibroblast is becoming recognized 
as a target for translational medicine, since it appears 
as a significant cellular participant in granulation tissue 
and several other human diseases (14). Previously, the 
characterization of the fully differentiated myofibro-
blast immunophenotype included positivity to vimentin 
and α-smooth-muscle actin, and negativity to smooth-
muscle myosin and usually desmin (3). However, a 
spindle cell positive to SMA is an imprecise definition 
for the myofibroblast since a number of normal cells 
also express it (14). Additionally, lesions first regarded 
as myofibroblastic are shown to vary in their level of 
differentiation, and some appear to be smooth-muscle 
rather than myofibroblastic (2). Desmin negativity ra-
ther than positivity should be seen as a more appropriate 
Fig. 3. Trans-operative aspect of the inflammatory myofibro-
blastic tumor during surgical excision.
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indicator of myofibroblastic differentiation (14). Finally, 
as recently suggested, the main characteristics of the 
myofibroblast include a spindled or stellate morpho-
logy, immunostaining for alpha-smooth-muscle actin 
and the extra domain A variant of cellular fibronectin, 
and an ultrastructure of rough endoplasmic reticulum, 
peripheral contractile filaments and the cell-to-matrix 
junction known as the fibronexus, being important for 
maximum diagnostic confidence in some myofibroblas-
tic lesions (2).
The immunophenotype of the IMT presented herein is 
in accordance with the identification of a myofibroblast 
(2,14), and also by other IMT reports (5,13) with strong 
diffuse cytoplasmic reactivity to vimentin, SMA and 
HHF-35 in a focal or diffuse pattern and also negativity 
to desmin, although the latest could be identified in many 
cases, as well as focal cytokeratin immunoreactivity 
(15). Myogenin, myoglobin, and S-100 protein are also 
negative (1,15), as were in the present case. Futhermore, 
we believe that more investigations on tumor behavior 
should take into account the fibronectin immunoprofile, 
since it is known that this protein shows properties that 
could precipitate a cascade leading to a number of cellu-
lar activities, such as differentiation, migration, mitosis 
all important to tumor progression (14). Recently, this 
marker has been associated to the invasive phenotype 
of oral carcinoma cell lines, although the authors could 
not establish if the presence of its expression is an asso-
ciated phenomena or a causative agent in the invasive 
process (4). 
Immunohistochemical cytoplasmic positivity for ALK 
(Anaplastic lymphoma kinase) is linked to neoplastic 
transformation since it provides strong evidence for an 
oncogenic activating mechanism (5). Thus, at least a 
proportion of IMTs presenting ALK genetic alterations 
are genuine neoplasms (15). However, ALK expression 
has been detected in approximately 50% of IMTs, and 
therefore shows not to be a specific marker for this le-
sion (1,15). The present case did not demonstrate im-
munoreactivity for ALK, as shown by most of the oral 
cases reported in the literature with only a few reports 
of oral IMT ALK-positive (5,13). Whether ALK-posi-
tive IMTs represent distinct clinicopathologic entities, 
with different therapeutic and prognostic implications, 
warrants further investigation (13) in order to clarify the 
contribution of ALK deregulation to the pathogenesis of 
oral IMT (5).
In addition to the controversy regarding the biologic 
nature of IMT, proliferating spindle cells may mimic 
a sarcoma, potentially leading to a diagnostic dilemma 
(13). Various benign and malignant spindle cell prolife-
rations should be included in the differential histologi-
cal diagnosis scheme of oral IMT such as proliferative 
fasciitis, nodular fasciitis, infantile fibromatosis, myo-
fibromatosis, Rosai-Dorfman disease, fibrous histiocy-
toma, solitary fibrous tumor, follicular dendritic cell tu-
mor, low-grade myofibroblastic sarcoma, fibrosarcoma, 
leiomyosarcoma, rhabdomyosarcoma, and spindle cell 
carcinoma (4,10). So, the knowledge of the different his-
tologic patterns of IMT, identification of a predominant 
inflammatory component and immunohistochemical 
study allow distinction between these entities, being 
helpful to the accurate diagnosis (5), as emphasized by 
the present report, and also preventing a more aggres-
sive surgical procedure.
Management of IMT should entail complete surgical 
resection (5,6), and since IMT may present a low-grade 
malignancy, longer follow-up is needed (11). Extrapul-
monary IMTs seem to exhibit a more favorable clini-
cal course and treatment outcome, evolving with lower 
rates of recurrence, malignant transformation, metasta-
sis, and mortality (5). One noteworthy feature is that 
oral IMT seems to behave differently from IMT occur-
ring elsewhere in body (11), displaying variable local 
recurrence and not reported metastasis (6). There may 
be a need to recognize it as a separate entity. The di-
versity of IMTs microscopic appearance and the lack 
of correlation between these variables and the clinical 
evolution of these tumors to date, encourage further re-
search on biomarkers, such as fibronectin, that might 
provide guidelines to tumor progression, treatment and 
prognosis.
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